



The Manager
Company Announcements
Australian Stock Exchange
4th Floor
20 Bridge Street
SYDNEY NSW 2000

1 July 2008

RHT: FerriScan® Funding

Resonance Health has lodged its submission to the Australian Medical Services Advisory Committee (MSAC) seeking reimbursement for FerriScan in Australia.

Additionally, the Whittington Hospital in London has successfully achieved funding approval from the NHS for FerriScan, enabling the clinicians to utilise FerriScan in the routine clinical care of patients with iron overload. There are over 15,000 people suffering from sickle cell disease, thalassemia major or myelodysplastic syndromes in the UK. Many of these patients require regular blood transfusions in the management of their disease and suffer from iron overload as a result. Patients attending the Whittington Hospital will now have access to a cost effective, non-invasive and accurate measurement of their liver iron loading enabling their clinicians to optimise the management of their treatment.

This represents an important acknowledgement of the clinical importance of FerriScan and a significant revenue opportunity for Resonance Health.

Consultant Haematologist at the Whittington Hospital, Dr Farrukh Shah said *"Having ready access to FerriScan at the Whittington Hospital will greatly improve the efficiency of monitoring the body iron burden in our iron loaded patients in a cost effective manner and will enable us to minimise the use of liver biopsy"*.

Resonance Health is working with other hospitals in the UK to achieve similar funding success, enabling FerriScan to be more widely available across the UK.

Reimbursement for the FerriScan test continues to be a key area of focus for Resonance Health and an important step in the commercialisation of the test.

By Order of the Board

Resonance Health Limited